Use of SGLT2 inhibition in the management of hyponatremia in a patient with metastatic cancer
Abstract
Hyponatremia is a common electrolyte abnormality in patients with malignancy, and recent investigations into the off-label use of SGLT2 inhibitors for syndrome of inappropriate antidiuretic hormone (SIADH) have shown promising short-term results. We report the case of an 84-year-old woman with history of relapsed metastatic uterine carcinosarcoma with chronic hyponatremia who failed standard therapy. The patient was initiated on empagliflozin 11 months ago and has had sustained normalization of serum sodium levels. While less is known about the long-term use of these agents, this case highlights the potential for SGLT2 inhibitors to be used as a low-burden therapeutic option for cancer-associated chronic hyponatremia.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.